Completed PHASE1 INTERVENTIONAL 2-arm NCT00513669

Phase Ib Trial of Two Virosome Formulated Malaria Vaccine Components (PEV 301, PEV 302) in Tanzania (PMAL03)

A Phase Ib Double-blind Randomized Placebo Controlled Age-deescalating Trial of Two Virosome Formulated Anti-malaria Vaccine Components (PEV 301 and PEV 302) Administered in Combination to Healthy Semi-immune Tanzanian Volunteers

Sponsor: Mymetics Corporation

Conditions Falciparum Malaria

Interventions Inflexal V (active comparator) PEV 301& 302 in virosomes

Updated 5 times since 2017 Last updated: Mar 14, 2013 Started: Jan 31, 2008 Primary completion: Mar 31, 2009 Completion: Mar 31, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Falciparum Malaria and is currently completed. Mymetics Corporation leads this study, which shows 5 recorded versions since 2008 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Jan 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Mymetics Corporation
Pevion Biotech Ltd
Swiss Tropical & Public Health Institute

Data source: Swiss Tropical & Public Health Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Bagamoyo, Tanzania